What Is BPC-157?

1. What kind of peptide is BPC-157?

BPC-157 is usually described as a synthetic fragment associated with a protective protein in human gastric juice. That origin story does not establish the safety of a manufactured product. The material in a vial or capsule still needs evidence for its identity, purity, absorption and effects in people. USADA’s BPC-157 overview explains its experimental status and why the label “research chemical” offers no assurance of suitability for human use.

It is not a GLP-1 receptor agonist or an approved weight-loss treatment. Sharing the word peptide with semaglutide says little about how it works. Peptides can act through very different biological pathways.

2. How might BPC-157 affect tissue repair?

Three experiments help explain the interest without requiring a biochemistry degree:

Fibroblasts make and maintain connective tissue. Blood vessels supply oxygen and nutrients. Changing their behavior could influence repair, which gives researchers a reason to test BPC-157. A cell moving across a laboratory dish, however, cannot tell you when a torn Achilles tendon can tolerate sprinting again.

3. What do the human BPC-157 studies show?

The most frequently cited published human intervention reports cover different conditions and different routes. They should not be combined into a single “success rate.”

The knee report supports investigating pain relief. It does not demonstrate that cartilage regrew or that a meniscus tear closed. Without a comparison group, natural recovery, rehabilitation, expectations and other treatments remain possible explanations.

The two participants in the IV pilot had already received BPC-157 before entering the study. That makes the report particularly weak evidence about how first-time users might react. It also provides no estimate of risks after months of use.

The September 2026 preprint with 1,039 users

Venkatakrishnan and colleagues used AI-assisted extraction with physician validation to analyze clinical notes. Their September 7 preprint identified 1,039 documented users. It had not been peer-reviewed when this page was written.

Among 354 people with a recorded direction of response, 79% had documented improvement. Outcomes were unavailable for 685 people, or 65.9% of all users. Other therapeutic agents were documented in 50.5%.

Those missing outcomes prevent treating 79% as a success rate for everyone who uses BPC-157. Co-treatments, selection bias and imperfect extraction also prevent attributing improvement to the peptide. The study describes use and reported experiences; it does not establish tissue repair.

Registered trials still need results

The older oral Phase 1 registration, NCT02637284, lists an estimated enrollment of 42, an unknown current status and no posted results. A planned sample size does not mean 42 people completed treatment safely.

A newer hamstring study registration, NCT07437547, describes a placebo-controlled trial with 120 planned participants, MRI outcomes and return to sport. Its sponsor-submitted record lists recruiting status, last updated in February 2026, with no results posted. The registration describes a proposed investigation; it does not independently verify recruitment or demonstrate benefit.

4. Does BPC-157 work for gut health?

Human gut research includes an older study that often disappears from summaries claiming BPC-157 has never been tested against placebo. The FDA’s 2026 briefing, pages 27–28, describes a 2005 conference abstract by Ruenzi and colleagues: 53 people with ulcerative colitis were randomized to a BPC-157 enema or placebo for two weeks.

The reported between-group confidence interval included zero. The abstract lacked enough methodological detail to establish effectiveness, and an enema study cannot validate capsules for reflux, IBS or “leaky gut.”

“Gut health” also groups together different problems. A treatment for inflammation in ulcerative colitis would not automatically treat bloating, food intolerance or GLP-1-related nausea. None of the human studies above establishes BPC-157 as a treatment for side effects from semaglutide or tirzepatide.

5. Oral BPC-157 vs injections: what is known?

There is no reliable human head-to-head evidence showing which route works better for injury recovery. The routes in published studies were highly specific: into a knee joint, into the bladder or into a vein. Those results do not establish the effects of an under-the-skin injection sold for general recovery.

For capsules, surviving stomach conditions and reaching a target tissue are separate questions. Bioavailability describes how much of a dose reaches systemic circulation. An oral product could conceivably have a local gut effect without substantial absorption, but that effect would still need testing in people with the condition being treated.

A capsule labeled “stable,” “acetate” or “arginate” needs evidence for that formulation. A change in chemical form or packaging does not supply the missing human comparison. The FDA specifically flags uncertainty about active ingredients and peptide impurities.

6. BPC-157 half-life and dosage claims

The frequently repeated half-life of less than 30 minutes comes from He and colleagues’ 2022 study in rats and dogs. Researchers measured the intact peptide after intravenous and intramuscular administration. They also found intramuscular bioavailability differed between species.

That experiment does not establish the half-life of a human subcutaneous injection or an oral capsule. Nor does a short plasma half-life tell you how long a downstream biological effect lasts. Drug clearance, tissue exposure and the duration of a repair response are different measurements.

No approved human recovery dose or cycle length exists. Small studies using different routes and treating different conditions cannot validate the daily schedules circulated in peptide forums. Converting an animal dose to a human body weight does not resolve those gaps.

For anyone examining a peptide half-life model, a BPC-157 curve built from animal data should be treated as an assumption. It cannot tell you how much active peptide remains in your body or when another dose would be safe.

7. BPC-157 side effects and unresolved risks

Human studies are too limited to provide dependable side-effect frequencies. The absence of reported problems in two IV recipients cannot exclude uncommon reactions or harm from repeated exposure.

The FDA warns about potential immune reactions, peptide impurities and uncertainty about product identity. A purity percentage alone cannot answer all those questions or establish that a finished injectable product is sterile.

The July 2026 FDA briefing describes three injectable-product adverse-event reports, including injection-site swelling, shortness of breath and pigmentation changes. Co-use and incomplete reporting limit attribution. These reports cannot establish causation or event rates.

Cancer risk is also unresolved. The blood-vessel experiments give researchers a reason to examine effects on tumor biology, since tumors can depend on blood supply. They do not show that BPC-157 causes cancer in humans. The available human follow-up is also inadequate to claim that long-term exposure is cancer-safe.

8. BPC-157 and TB-500: does stacking improve recovery?

The “Wolverine stack” combines BPC-157 with products marketed as TB-500. The 2021 knee report included only four patients given BPC-157 plus thymosin beta-4. It was neither randomized nor designed to establish an advantage from combining them. Commercial TB-500 products should not automatically be assumed equivalent to the material used in that report.

Adding a second compound also makes a personal experiment harder to interpret. If pain improves while someone starts two peptides, reduces training volume and begins physiotherapy, the log cannot separate those effects. The same problem applies to attributing a new symptom.

There is no established human safety or effectiveness advantage for this stack. The knee study’s four combination recipients cannot settle that question.

9. Is BPC-157 FDA-approved, and is it banned in sport?

BPC-157 has no FDA-approved medical use as of September 20, 2026. The FDA’s July 2026 compounding meeting considered its free base and acetate forms for the 503A bulk-substances list. Compounding eligibility and approval of a finished drug are separate regulatory decisions; advisory recommendations are nonbinding.

For athletes, USADA identifies BPC-157 as prohibited at all times under WADA’s S0 category. That includes out-of-competition use. Calling it a recovery aid or obtaining it from a clinic does not remove that prohibition.

10. What would convincing recovery evidence look like?

For an injury claim, look for a trial in people with the same diagnosed injury, a placebo or appropriate comparison group, and the same rehabilitation program in both groups. The useful outcomes are concrete: time to return to sport, strength, function, repeat injury and imaging where appropriate. Pain relief alone cannot establish structural repair.

If you are reviewing a past personal experiment, bring the timeline to the clinician assessing the injury. Record the exact product, exposure dates, symptoms, training changes, rehabilitation and other treatments. A peptide log can preserve those details. Keep pain scores separate from what the injured tissue can tolerate, and include the setbacks as well as the days that felt better.

11. BPC-157 FAQ

• What is BPC-157 used for?

  BPC-157 is marketed for tendon and muscle recovery, joint pain and gut health. These remain experimental uses. Animal and cell studies provide a research rationale, but human trials have not established these benefits.

• Does BPC-157 heal tendons or a torn meniscus?

  Human evidence has not established that it repairs either. A small retrospective knee-pain study reported symptom improvement but did not demonstrate tendon or meniscus healing with follow-up imaging.

• Does oral BPC-157 work as well as injections?

  No reliable human head-to-head trial establishes that. Stability in stomach fluid does not establish how much reaches the bloodstream, and results from injections into a joint or bladder cannot be applied to capsules.

• What is the recommended BPC-157 dosage?

  There is no FDA-approved dose or validated human recovery protocol. Experimental doses used in small studies do not establish an effective or safe dose for self-treatment.

• What is the half-life of BPC-157?

  A 2022 pharmacokinetic study reported a half-life below 30 minutes for intact BPC-157 in rats and dogs. A reliable human half-life for commonly marketed oral and subcutaneous products has not been established.

• Does BPC-157 cause cancer?

  Human evidence does not establish that it causes cancer or that long-term exposure is safe. Its effects on blood-vessel growth in preclinical experiments raise a question for further study; they do not measure cancer risk in people.

• Can BPC-157 be stacked with TB-500?

  There is no reliable controlled human evidence that the combination improves recovery over BPC-157 alone. The small knee-pain report included four people receiving BPC-157 plus thymosin beta-4, which cannot validate commercial TB-500 stacks.

• Is BPC-157 FDA-approved or allowed in tested sport?

  BPC-157 has no FDA-approved medical use as of September 20, 2026. Compounding reviews do not constitute drug approval. USADA identifies BPC-157 as prohibited at all times under WADA's S0 category.

12. Sources